Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68-Reference-Cited by-同舟云学术

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Published:2011-10-19 Issue:1 Volume:11 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Ascierto Maria Libera,Worschech Andrea,Yu Zhiya,Adams Sharon,Reinboth Jennifer,Chen Nanhai G,Pos Zoltan,Roychoudhuri Rahul,Di Pasquale Giovanni,Bedognetti Davide,Uccellini Lorenzo,Rossano Fabio,Ascierto Paolo A,Stroncek David F,Restifo Nicholas P,Wang Ena,Szalay Aladar A,Marincola Francesco M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-11-451.pdf

Reference36 articles.

1. Thorne SH, Bartlett DL, Kirn DH: The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?. Curr Gene Ther. 2005, 5 (4): 429-443. 10.2174/1566523054546215.

2. Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC: Poxvirus vectors: orphaned and underappreciated. J Clin Invest. 2000, 105 (8): 1031-1034. 10.1172/JCI9819.

3. O'Shea CC: DNA tumor viruses -- the spies who lyse us. Curr Opin Genet Dev. 2005, 15 (1): 18-26. 10.1016/j.gde.2004.12.010.

4. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991, 252 (5007): 854-856. 10.1126/science.1851332.

5. Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA: Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer. 2011, 11: 68-10.1186/1471-2407-11-68.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer;International Journal of Gynecologic Cancer;2023-09

2. Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer;JAMA Oncology;2023-07-01

3. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer;Gynecologic Oncology;2021-12

4. A profile of 8-oxo-dGTPase activities in the NCI-60 human cancer panel: Meta-analytic insight into the regulation and role of MTH1 (NUDT1) gene expression in carcinogenesis;Free Radical Biology and Medicine;2020-02

5. Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase;Cancers;2020-01-17